Treatment of Acute Myeloid Leukemia in the Community Setting
The treatment landscape for acute myeloid leukemia (AML) is rapidly changing. Many new agents and lower-intensity regimens have been approved and can be safely used by hematologists and oncologists in both academic and community settings. The US Food and Drug Administration (FDA) held a virtual symposium on AML treatment in the community in November 2022. Several members of the FDA, along with practicing hematologists and oncologists in both academic and community settings, participated in the symposium. The goal of the symposium was to discuss challenges and opportunities in the treatment of patients with AML in community oncology settings. A summary of these discussions and key considerations are presented here.
Authors
- Rohan Gupta (ORCID: https://orcid.org/0000-0002-6635-6558)
- Iuliana Shapira (ORCID: https://orcid.org/0000-0001-7996-3616)
- Gina Keiffer
- R. Angelo de Claro (ORCID: https://orcid.org/0000-0001-8362-1977)
- Ravin J. Garg
- Taha Al‐Juhaishi
- Kelly J. Norsworthy (ORCID: https://orcid.org/0000-0002-8462-9994)
- Marc Robert Theoret (ORCID: https://orcid.org/0000-0003-4973-5297)
- Ashley Woods (ORCID: https://orcid.org/0009-0001-4878-5463)
- Elizabeth Pulte
- Servillano Dela Cruz
- Vicki A. Morrison
Institutions
- University of Minnesota (US)
- United States Food and Drug Administration (US)
- Center for Drug Evaluation and Research (US)
- Thomas Jefferson University (US)
- Hennepin County Medical Center (US)
- Maryland Oncology Hematology (US)
- Sidney Kimmel Cancer Center (US)
- Center for Cancer and Blood Disorders (US)
- Florida Cancer Specialists & Research Institute (US)
- University of Oklahoma Health Sciences Center (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-08-19
- DOI
- https://doi.org/10.1093/oncolo/oyae051
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00